Statins & HIV: New Heart Benefit Mechanism Found
- A new study suggests that statins, commonly used to lower cholesterol, may offer additional heart health benefits for individuals with HIV.
- The research builds on earlier findings that showed a daily statin pill helped prevent cardiovascular events in people with HIV.
- Steven Grinspoon, chief of the Metabolism Unit at Massachusetts General Hospital, noted that people with HIV often have an excess of unstable plaques, making them more susceptible to...
Statins may offer significant cardiovascular benefits for people living with HIV, a critical finding from a new study. Researchers discovered a promising mechanism: Statins appear to stabilize plaques in blood vessels, reducing the risk of heart attacks and strokes. this insight, published in JAMA Cardiology, builds on prior research and helps explain why a daily statin pill can prevent cardiovascular events in this population. The study, analyzing data from the REPRIEVE trial, found that pitavastatin increased procollagen C-endopeptidases enhancer 1 (PCOLCE) levels, an enzyme crucial for collagen production.news Directory 3 provides updates on critically important medical developments. Discover the potential of this research and its implications for individuals without HIV by staying informed.
Statins May Improve Heart Health in People With HIV
Updated June 08, 2025
A new study suggests that statins, commonly used to lower cholesterol, may offer additional heart health benefits for individuals with HIV. Researchers have uncovered a potential mechanism by which statins could stabilize plaques in blood vessels, reducing the risk of heart attacks and strokes. The findings, stemming from research at Mass General Brigham, were published in JAMA Cardiology.
The research builds on earlier findings that showed a daily statin pill helped prevent cardiovascular events in people with HIV. The latest analysis delves into how statins might work to stabilize vulnerable plaques.
Dr. Steven Grinspoon, chief of the Metabolism Unit at Massachusetts General Hospital, noted that people with HIV often have an excess of unstable plaques, making them more susceptible to heart problems at a younger age.He said understanding how statins help this group could lead to more targeted therapies for cardiovascular health.
The study involved a secondary analysis of data from the REPRIEVE trial, which previously demonstrated that pitavastatin, a cholesterol-lowering drug, reduced the risk of cardiovascular events by 36% in people with HIV over roughly five and a half years. This effect appeared to be greater than what would be expected from cholesterol reduction alone.
Grinspoon and his team measured the levels of 255 proteins in blood samples from 558 REPRIEVE participants. They discovered that pitavastatin increased levels of procollagen C-endopeptidases enhancer 1 (PCOLCE), an enzyme involved in collagen production. Collagen may help stabilize plaques during atherosclerosis.
Further experiments revealed that higher PCOLCE levels were associated with fewer noncalcified plaques and more stable, fibrous plaques. Thes changes, along with a reduction in plaque lipid content, may prevent plaque rupture.
“By showing that statins raise PCOLCE, which is associated with favorable changes in plaques, our findings expand our knowledge about how the benefits of statins go beyond cholesterol lowering,” said Grinspoon.
Grinspoon added that while more research is needed, the findings could potentially apply to people without HIV as well.
What’s next
Future research will explore the broader implications of these findings and investigate whether similar mechanisms are at play in individuals without HIV, potentially leading to expanded guidelines for statin use in cardiovascular disease prevention.